Monica Markovski
FDA investigator
Appears on 1 document from 2016, mostly at sites in South Korea. Most often cites control of microbiological contamination (21 CFR 211.113).
- 1
- Documents on file
- 13.0
- Observations per 483
- 2016
- First seen
- 2016
- Most recent
What they cite most
From 12 observations- 21 CFR 211.113Control of microbiological contamination4
- 21 CFR 211.160General requirements3
- 21 CFR 211.192Production record review3
- 21 CFR 211.25Personnel qualifications1
- 21 CFR 211.42Design and construction features1
- 21 CFR 211.63Equipment design, size, and location1
Activity by year
2016: 1
Where
South Korea 1
Often inspects with
Is Monica Markovski coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2016-06-22 | 483 Samsung Biologics Co., Ltd.Jun 22, 2016 · Incheon, South Korea | Incheon, South Korea | 13 |
About this profile
What does Monica Markovski inspect?
Monica Markovski appears on 1 document on file covering 1 site, mostly in South Korea.
What do they cite most often?
21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.160 and 21 CFR 211.192.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Monica Markovski is dated Jun 22, 2016.